Skip to main content
Premium Trial:

Request an Annual Quote

Foundation Medicine Partners with South Dakota Hospital on Cancer Genomics

NEW YORK (GenomeWeb) – Avera McKennan Hospital today announced it has signed an agreement with Foundation Medicine to partner on cancer genomics.

The hospital's Sioux Falls, S.D.-based Avera Cancer Institute is conducting studies with the molecular diagnostics firm that focus on personalized medicine in oncology and fundamental cancer biology.

Other areas of potential future collaboration include joint research, data sharing and database development, education, and patient support programs.

"Foundation Medicine specializes in genomic sequencing that is instrumental to our program, as we tailor cancer treatment based on the specific genetic changes that drive tumors," Brian Leyland-Jones, VP of molecular and experimental medicine at Avera Cancer Institute, said in a statement.  

"Our tests have the potential to open up new treatment options for patients with cancer by matching them with a targeted therapy or clinical trial," Foundation Medicine Medical Director Jeff Ross said.

Financial and other details of the agreement were not disclosed.

On Monday, Foundation Medicine announced an R&D collaboration worth at least $150 million with Roche, as part of a $1.2 billion deal giving Roche a majority stake in the firm.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.